
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical Inc. exhibits a positive outlook due to potential upside drivers such as faster-than-expected spine market growth and higher sales in its Enabling Technologies segment, which could lead to improved margins. The company is currently trading below historical valuation levels, accompanied by impressive double-digit free cash flow growth and an 8% free cash flow yield, indicating a favorable risk/reward profile for investors. Despite a slight miss in 2Q25 base business results compared to consensus, there remains a projection of profit upside relative to increased future estimates, reinforcing confidence in the company's financial trajectory.
Bears say
Globus Medical Inc. faces significant headwinds that contribute to a negative outlook on its stock, including anticipated slower growth in the spine market and potential revenue dis-synergies stemming from the recent NuVasive merger. Concerns regarding the company's ability to maintain margin expansion are compounded by lower-than-expected sales in its Enabling Technologies segment and challenges in launching key products within the musculoskeletal solutions category. Additionally, there are risks associated with competitive dynamics in the spine market and potential delays in expanding into new areas, all of which could impact overall financial performance and growth rates.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares